Total Payments
$29,942
2024 Payments
$28,924
Companies
5
Transactions
22
Medicare Patients
824
Medicare Billing
$99,135
Payment Breakdown by Category
Consulting$24,800 (82.8%)
Travel$2,920 (9.8%)
Research$1,572 (5.2%)
Food & Beverage$585.37 (2.0%)
Education$64.54 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $24,800 | 3 | 82.8% |
| Travel and Lodging | $2,920 | 4 | 9.8% |
| Unspecified | $1,572 | 9 | 5.2% |
| Food and Beverage | $585.37 | 4 | 2.0% |
| Education | $64.54 | 2 | 0.2% |
Payments by Type
General
$28,370
13 transactions
Research
$1,572
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $28,235 | 12 | $0 (2024) |
| Eli Lilly and Company | $870.00 | 2 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $680.96 | 6 | $0 (2024) |
| Madrigal Pharmaceuticals | $134.64 | 1 | $0 (2024) |
| GlaxoSmithKline, LLC. | $20.82 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,924 | 16 | Novo Nordisk Inc ($28,108) |
| 2023 | $383.19 | 3 | Eli Lilly and Company ($300.00) |
| 2022 | $602.27 | 2 | Eli Lilly and Company ($570.00) |
| 2021 | $32.27 | 1 | Novo Nordisk Inc ($32.27) |
All Payment Transactions
22 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | Madrigal Pharmaceuticals | REZDIFFRA (Drug) | Food and Beverage | In-kind items and services | $134.64 | General |
| Category: LIVER DISEASE | ||||||
| 10/21/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $330.00 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $121.99 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $97.00 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $48.99 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $48.99 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 09/27/2024 | Regeneron Pharmaceuticals, Inc. | — | — | In-kind items and services | $33.99 | Research |
| Study: A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | ||||||
| 09/20/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $11,043.75 | General |
| 09/20/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $876.82 | General |
| 09/20/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $383.23 | General |
| 09/20/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $199.95 | General |
| 04/29/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $2,712.50 | General |
| 04/13/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $11,043.75 | General |
| 04/13/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $994.03 | General |
| 04/13/2024 | Novo Nordisk Inc | — | Travel and Lodging | In-kind items and services | $665.79 | General |
| 04/13/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $188.41 | General |
| 11/12/2023 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $20.82 | Research |
| Study: 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $300.00 | Research |
| Study: A SINGLE-ASCENDING AND REPEATED SUBCUTANEOUS DOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3849891 IN PARTICIPANTS WITH NONALCOHOLIC FATTY LIVER DISEASE WHO HAVE THE PNPLA3 I148M GENOTYPE | ||||||
| 01/25/2023 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $62.37 | General |
| 06/15/2022 | Novo Nordisk Inc | Wegovy (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Obesity | ||||||
| 04/24/2022 | Eli Lilly and Company | — | — | In-kind items and services | $570.00 | Research |
| Study: A SINGLE-ASCENDING AND REPEATED SUBCUTANEOUS DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3849891 IN PARTICIPANTS WITH NONALCOHOLIC FATTY LIVER DISEASE WHO HAVE THE PNPLA3 I148M GENOTYPE | ||||||
| 05/12/2021 | Novo Nordisk Inc | — | Education | In-kind items and services | $32.27 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MASTER PROTOCOL OF RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDIES OF SIRNA GENE SILENCING FOR THE TREATMENT OF NON- ALCOHOLIC STEATOHEPATITIS (NASH) IN PARTICIPANTS WITH GENETIC RISK FACTORS | Regeneron Pharmaceuticals, Inc. | $680.96 | 6 |
| A SINGLE-ASCENDING AND REPEATED SUBCUTANEOUS DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3849891 IN PARTICIPANTS WITH NONALCOHOLIC FATTY LIVER DISEASE WHO HAVE THE PNPLA3 I148M GENOTYPE | Eli Lilly and Company | $570.00 | 1 |
| A SINGLE-ASCENDING AND REPEATED SUBCUTANEOUS DOSE STUDY TO EVALUATE THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3849891 IN PARTICIPANTS WITH NONALCOHOLIC FATTY LIVER DISEASE WHO HAVE THE PNPLA3 I148M GENOTYPE | Eli Lilly and Company | $300.00 | 1 |
| 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | GlaxoSmithKline, LLC. | $20.82 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 228 | 261 | $98,927 | $27,874 |
| 2022 | 7 | 244 | 313 | $98,326 | $30,868 |
| 2021 | 9 | 232 | 284 | $99,887 | $28,462 |
| 2020 | 4 | 120 | 196 | $37,682 | $11,932 |
Total Patients
824
Total Services
1,054
Medicare Billing
$99,135
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 52 | 57 | $16,701 | $6,721 | 40.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 34 | 39 | $11,427 | $4,083 | 35.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 20 | 20 | $25,140 | $3,880 | 15.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 39 | $8,463 | $3,374 | 39.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 24 | $10,128 | $3,106 | 30.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 18 | 18 | $7,308 | $2,925 | 40.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 20 | 20 | $8,120 | $2,342 | 28.8% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 12 | 12 | $9,792 | $964.72 | 9.9% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 27 | 32 | $1,848 | $478.78 | 25.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 47 | 100 | $21,700 | $7,561 | 34.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 37 | 39 | $16,458 | $5,699 | 34.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 24 | 28 | $8,204 | $3,394 | 41.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 27 | 27 | $10,962 | $3,133 | 28.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 28 | 29 | $8,497 | $3,013 | 35.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $6,902 | $2,791 | 40.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 14 | 14 | $17,598 | $2,648 | 15.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 16 | $3,456 | $1,375 | 39.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 15 | 15 | $3,240 | $893.31 | 27.6% |
| 91200 | Measurement of liver stiffness | Office | 2022 | 19 | 28 | $1,309 | $361.08 | 27.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 30 | 68 | $14,756 | $5,321 | 36.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 35 | 35 | $14,210 | $4,915 | 34.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 45 | 51 | $11,016 | $3,785 | 34.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 22 | 22 | $9,284 | $3,335 | 35.9% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 16 | 16 | $20,112 | $3,030 | 15.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 20 | 23 | $6,739 | $2,571 | 38.2% |
About Dr. Niharika Samala, MD
Dr. Niharika Samala, MD is a Internal Medicine healthcare provider based in Royal Oak, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/09/2008. The National Provider Identifier (NPI) number assigned to this provider is 1023266541.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Niharika Samala, MD has received a total of $29,942 in payments from pharmaceutical and medical device companies, with $28,924 received in 2024. These payments were reported across 22 transactions from 5 companies. The most common payment nature is "Consulting Fee" ($24,800).
As a Medicare-enrolled provider, Samala has provided services to 824 Medicare beneficiaries, totaling 1,054 services with total Medicare billing of $99,135. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine, Gastroenterology
- Location Royal Oak, MI
- Active Since 09/09/2008
- Last Updated 03/07/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1023266541
Products in Payments
- REZDIFFRA (Drug) $134.64
- Wegovy (Drug) $32.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Royal Oak
Sudipto Mukherjee, Md, MD
Internal Medicine — Payments: $205,779
Internal Medicine $205,779
Dr. Ryan Madder, M.d, M.D
Internal Medicine — Payments: $157,098
Internal Medicine $157,098
Dr. Mohamad Rasm Alsibae, Md, MD
Internal Medicine — Payments: $122,437
Internal Medicine $122,437
Nishaki Mehta, M.d, M.D
Internal Medicine — Payments: $84,717
Internal Medicine $84,717
Shanu Agarwal, Md, MD
Internal Medicine — Payments: $22,785
Internal Medicine $22,785
Bhavinkumar Dalal, Md, MD
Internal Medicine — Payments: $21,864
Internal Medicine $21,864